1. Market Research
  2. > All Companies
  3. > Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review

Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Elite Pharmaceuticals, Inc. (Elite) develops oral sustained and controlled release products. Elite's prime focus lies in the areas of pain management, cardiovascular, infection and allergy. Its product portfolio includes eight commercialized products which are either owned, licensed or contract manufactured including phentermine 37.5mg tablets, Lodrane D, methadone 10mg tablets and hydromorphone hydrochloride 8mg tablets, among others. Its in-house capabilities include product development of oral solid dosage forms, clinical batch manufacturing, and GMP manufacturing facilities which provides its proprietary technology a strong base.

Elite Pharmaceuticals, Inc. Key Recent Developments

Jun 16, 2015 Elite Pharmaceuticals Granted New Patent For Abuse Deterrent Technology
Jun 15, 2015 Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2015
Feb 17, 2015 Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2015
Dec 16, 2014 Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Elite Pharmaceuticals, Inc. - Key Facts 6
Elite Pharmaceuticals, Inc. - Key Employees 7
Elite Pharmaceuticals, Inc. - Key Employee Biographies 8
Elite Pharmaceuticals, Inc. - Major Products and Services 9
Elite Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 10
Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc. - History 12
Elite Pharmaceuticals, Inc. - Company Statement 15
Elite Pharmaceuticals, Inc. - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Section 2 - Company Analysis 18
Elite Pharmaceuticals, Inc. - Business Description 18
Elite Pharmaceuticals, Inc. - Corporate Strategy 19
Elite Pharmaceuticals, Inc. - SWOT Analysis 20
SWOT Analysis - Overview 20
Elite Pharmaceuticals, Inc. - Strengths 20
Strength - Patent Portfolio 20
Strength - Strategic Collaborations 20
Strength - Portfolio of Abuse-Deterrent Products 20
Elite Pharmaceuticals, Inc. - Weaknesses 21
Weakness - Termination of Agreement 21
Weakness - History of Losses 21
Elite Pharmaceuticals, Inc. - Opportunities 22
Opportunity - Strong Product Pipeline 22
Opportunity - New products 22
Opportunity - Market Potential for Obesity and Pain Treatments 22
Elite Pharmaceuticals, Inc. - Threats 23
Threat - Intense Competition 23
Threat - Stringent Governmental Regulations 23
Threat - Uncertain RandD Outcomes 23
Elite Pharmaceuticals, Inc. - Key Competitors 24
Section 3 - Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 - Company's Lifesciences Financial Deals and Alliances 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 32
Elite Pharmaceuticals, Inc., Recent Deals Summary 33
Section 5 - Company's Recent Developments 34
Jun 16, 2015: Elite Pharmaceuticals Granted New Patent For Abuse Deterrent Technology 34
Jun 15, 2015: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2015 35
Feb 17, 2015: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2015 36
Dec 16, 2014: Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation 37
Nov 18, 2014: Elite Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2015 38
Oct 24, 2014: Elite Pharmaceuticals Announces New Management Appointments 39
Aug 14, 2014: Elite Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2015 40
Jun 30, 2014: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2014 41
May 23, 2014: Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders 42
Mar 10, 2014: Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally 43
Section 6 - Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Elite Pharmaceuticals, Inc., Key Facts 6
Elite Pharmaceuticals, Inc., Key Employees 7
Elite Pharmaceuticals, Inc., Key Employee Biographies 8
Elite Pharmaceuticals, Inc., Major Products and Services 9
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Elite Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 11
Elite Pharmaceuticals, Inc., History 12
Elite Pharmaceuticals, Inc., Subsidiaries 17
Elite Pharmaceuticals, Inc., Key Competitors 24
Elite Pharmaceuticals, Inc., Ratios based on current share price 25
Elite Pharmaceuticals, Inc., Annual Ratios 26
Elite Pharmaceuticals, Inc., Interim Ratios 29
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 32
Elite Pharmaceuticals, Inc., Recent Deals Summary 33
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 47
Efficiency Ratios 47

List of Figures
Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc., Performance Chart (2011 - 2015) 28
Elite Pharmaceuticals, Inc., Ratio Charts 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 32

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals

  • $ 3 500
  • Company report
  • May 2015
  • by Global Data

Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals” ...

Liver Cancer - Pipeline Review, H1 2015

Liver Cancer - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Liver Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Liver Cancer - Pipeline Review, H1 2015’, provides an overview of the Liver Cancer’s therapeutic pipeline. This report ...

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015’, provides an overview of the Multiple ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.